SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages.
Acta Biochim Biophys Sin (Shanghai)
; 54(4): 556-564, 2022 Apr 25.
Article
in English
| MEDLINE | ID: covidwho-1862958
ABSTRACT
Age has been found to be one of the main risk factors for the severity and outcome of COVID-19. However, differences in SARS-CoV-2 specific antibody responses among COVID-19 patients of different age groups remain largely unknown. In this study, we analyzed the IgG/IgM responses to 21 SARS-CoV-2 proteins and 197 peptides that fully cover the spike protein against 731 sera collected from 731 COVID-19 patients aged from 1 to We show that there is no overall difference in SARS-CoV-2 antibody responses in COVID-19 patients in the 4 age groups. By antibody response landscape maps, we find that the IgG response profiles of SARS-CoV-2 proteins are positively correlated with age. The S protein linear epitope map shows that the immunogenicity of the S-protein peptides is related to peptide sequence, disease severity and age of the COVID-19 patients. Furthermore, the enrichment analysis indicates that low S1 IgG responses are enriched in patients aged <50 and high S1 IgG responses are enriched in mild COVID-19 patients aged >60. In addition, high responses of non-structural/accessory proteins are enriched in severe COVID-19 patients aged >70. These results suggest the distinct immune response of IgG/IgM to each SARS-CoV-2 protein in patients of different age, which may facilitate a deeper understanding of the immune responses in COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Age Factors
/
COVID-19
/
Antibody Formation
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Aged
/
Humans
/
Middle aged
Language:
English
Journal:
Acta Biochim Biophys Sin (Shanghai)
Journal subject:
Biophysics
/
Biochemistry
Year:
2022
Document Type:
Article
Affiliation country:
Abbs.2022014
Similar
MEDLINE
...
LILACS
LIS